Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)Eiji Oki, Yoshihiko Maehara, Takeshi Nagasaka et al.|British Journal of Cancer|2019Cited by 61
Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related proteinSatoshi Saijoh, Keiichi Tamai, Mao Nakamura‐Shima et al.|Biochemical and Biophysical Research Communications|2021Cited by 9
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM TrialTakao Takahashi, Yoshihiko Maehara, Kazuyuki Ishida et al.|Cancers|2022Cited by 4